SG43220A1 - Hepatitis surface antigen formed by recombinat dna techniques vaccines diagnostics cell lines and methods of forming same - Google Patents
Hepatitis surface antigen formed by recombinat dna techniques vaccines diagnostics cell lines and methods of forming sameInfo
- Publication number
- SG43220A1 SG43220A1 SG1996005752A SG1996005752A SG43220A1 SG 43220 A1 SG43220 A1 SG 43220A1 SG 1996005752 A SG1996005752 A SG 1996005752A SG 1996005752 A SG1996005752 A SG 1996005752A SG 43220 A1 SG43220 A1 SG 43220A1
- Authority
- SG
- Singapore
- Prior art keywords
- vaccines
- methods
- cell lines
- surface antigen
- dna techniques
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP85104521 | 1985-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG43220A1 true SG43220A1 (en) | 1997-10-17 |
Family
ID=8193449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996005752A SG43220A1 (en) | 1985-04-15 | 1986-04-15 | Hepatitis surface antigen formed by recombinat dna techniques vaccines diagnostics cell lines and methods of forming same |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP0198474B1 (zh) |
JP (1) | JPS6255088A (zh) |
CN (1) | CN86102640A (zh) |
AP (1) | AP8600035A0 (zh) |
AT (1) | ATE139795T1 (zh) |
DE (1) | DE3650536T2 (zh) |
ES (1) | ES8802440A1 (zh) |
FI (1) | FI861417A0 (zh) |
HK (1) | HK1003794A1 (zh) |
IE (1) | IE75355B1 (zh) |
IL (1) | IL78472A (zh) |
SG (1) | SG43220A1 (zh) |
YU (1) | YU60986A (zh) |
ZA (1) | ZA862797B (zh) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816564A (en) * | 1986-01-31 | 1989-03-28 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
JPS62236493A (ja) * | 1986-04-08 | 1987-10-16 | Green Cross Corp:The | HBウイルスのPre S領域を含むHBsAgの製造方法 |
IL79740A0 (en) * | 1986-08-17 | 1986-11-30 | Yeda Res & Dev | Hepatitis vaccine |
US5026828A (en) * | 1987-02-27 | 1991-06-25 | Merck & Co., Inc. | Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast |
EP0288198A3 (en) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
CA1341356C (en) * | 1987-05-01 | 2002-04-09 | Richard F. Selden | Transkaryotic implantation |
EP0304578B1 (en) * | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
ES2167304T3 (es) * | 1987-06-22 | 2002-05-16 | Medeva Holdings Bv | Peptido que contiene el antigeno de superficie de la hepatitis b. |
AU619753B2 (en) * | 1987-06-22 | 1992-02-06 | Medeva Holdings B.V. | Hepatitis b surface antigen vaccine |
US5011915A (en) * | 1987-10-26 | 1991-04-30 | Merck & Co., Inc. | Process for purifying recombinant hepatitis antigens |
JPH0216975A (ja) * | 1988-02-09 | 1990-01-19 | Eugene Tech Internatl Inc | 異成分混交性のプレーsに富んだb型肝炎表面抗原 |
US6306625B1 (en) | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
CA2026570C (en) * | 1989-02-07 | 2000-05-30 | Zeev Even-Chen | Method for production and purification of hepatitis b vaccine |
JP2957195B2 (ja) * | 1989-05-17 | 1999-10-04 | 株式会社シノテスト | B型肝炎ウイルス抗体検出システム |
US5091300A (en) * | 1989-08-03 | 1992-02-25 | Merck & Co., Inc. | Radio-immuno assay for hepatitis b virus pres2 antibodies |
EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
EP0533263A3 (en) * | 1991-09-20 | 1994-06-08 | Merck & Co Inc | A multivalent hepatitis b virus vaccine |
WO1993012815A1 (en) * | 1991-12-27 | 1993-07-08 | Gensci Limited | Method for obtaining recombinant surface antigen of hepatitis b, antigen and vaccine based on it |
ATE168271T1 (de) | 1992-05-23 | 1998-08-15 | Smithkline Beecham Biolog | Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
ES2146231T3 (es) * | 1992-07-08 | 2000-08-01 | Innogenetics Nv | Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas. |
CN1063343C (zh) * | 1993-04-27 | 2001-03-21 | 中国科学院上海生物化学研究所 | 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白 |
CN1059927C (zh) * | 1994-03-10 | 2000-12-27 | 中国科学院上海生物化学研究所 | 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白 |
US6100043A (en) * | 1995-08-04 | 2000-08-08 | The Perkin-Elmer Corporation | Recombinant clone selection system |
US5843656A (en) * | 1995-08-07 | 1998-12-01 | The Perkin-Elmer Corporation | Recombinant clone selection system |
AU6844696A (en) * | 1995-08-07 | 1997-03-05 | Perkin-Elmer Corporation, The | Recombinant clone selection system |
CN1067721C (zh) * | 1996-07-04 | 2001-06-27 | 中国科学院上海生物化学研究所 | 含前表面抗原1和2免疫决定簇的乙肝表面抗原 |
GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
CA2347099C (en) | 1998-10-16 | 2014-08-05 | Smithkline Beecham Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
US6583279B1 (en) | 2001-01-26 | 2003-06-24 | Becton, Dickinson And Company | Sequences and methods for detection of hepatitis B virus |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US7176022B2 (en) | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
ES2359473T3 (es) | 2003-07-21 | 2011-05-23 | Transgene S.A. | Citoquinas multifuncionales. |
CN100381171C (zh) * | 2004-12-30 | 2008-04-16 | 成都生物制品研究所 | 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒 |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
PL2066344T3 (pl) | 2006-09-07 | 2011-10-31 | Glaxosmithkline Biologicals Sa | Skojarzona szczepionka zawierająca inaktywowany wirus polio |
SI2068918T1 (sl) | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US20100183667A1 (en) | 2006-10-12 | 2010-07-22 | Glaxo Smithkline Biologicals S.A. | Vaccine Comprising an Oil in Water Emulsion Adjuvant |
EP2086582B1 (en) | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccine comprising an oil in water emulsion adjuvant |
PE20090146A1 (es) | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
BRPI0810778A2 (pt) | 2007-05-02 | 2011-09-13 | Glaxosmithkline Biolog Sa | kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo |
EP2293813A4 (en) | 2008-05-23 | 2012-07-11 | Univ Michigan | NANOEMULSION VACCINES |
RU2732574C2 (ru) | 2009-06-05 | 2020-09-21 | Инфекшес Дизиз Рисерч Инститьют | Синтетические глюкопиранозиллипидные адъюванты |
EA201690310A1 (ru) | 2010-04-13 | 2016-12-30 | Селлдекс Терапьютикс Инк. | Антитела, связывающие cd27 человека, и их применение |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
CN110339160A (zh) | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
CN109134640A (zh) | 2012-10-23 | 2019-01-04 | 爱默蕾大学 | Gm-csf和il-4轭合物、组合物以及与其相关的方法 |
AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
EA201691348A1 (ru) | 2013-12-31 | 2016-11-30 | Инфекшес Дизиз Рисерч Инститьют | Однофлаконные вакцинные составы |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
US20200377606A1 (en) | 2016-04-18 | 2020-12-03 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
ES2929054T3 (es) | 2016-05-16 | 2022-11-24 | Access To Advanced Health Inst | Formulación que contiene un agonista de TLR y métodos de uso |
MX2018013640A (es) | 2016-05-16 | 2019-08-01 | Infectious Disease Res Inst | Liposomas pegiladas y metodos de uso. |
KR20220165789A (ko) | 2016-06-01 | 2022-12-15 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사이징제를 함유하는 나노명반 입자 |
MX2019015076A (es) | 2017-06-15 | 2020-08-03 | Infectious Disease Res Inst | Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos. |
AU2018330165A1 (en) | 2017-09-08 | 2020-04-02 | Access To Advanced Health Institute | Liposomal formulations comprising saponin and methods of use |
MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
EP3976092A1 (en) | 2019-05-25 | 2022-04-06 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
CN111961664A (zh) * | 2020-09-08 | 2020-11-20 | 武汉中投汉嘉科技有限公司 | 一种核酸提取液 |
WO2022217019A1 (en) | 2021-04-09 | 2022-10-13 | Celldex Therapeutics, Inc. | Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof |
WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD147855A5 (de) * | 1978-12-22 | 1981-04-22 | Biogen Nv | Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids |
IE52036B1 (en) * | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
EP0094428B1 (en) * | 1981-11-23 | 1992-02-12 | University Patents, Inc. | Control of dna sequence transcription |
WO1984002534A1 (en) * | 1982-12-23 | 1984-07-05 | Us Commerce | Human growth hormone produced by recombinant dna in mouse cells |
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
-
1986
- 1986-04-01 FI FI861417A patent/FI861417A0/fi not_active Application Discontinuation
- 1986-04-10 IL IL7847286A patent/IL78472A/en unknown
- 1986-04-14 AP APAP/P/1986/000035A patent/AP8600035A0/en unknown
- 1986-04-14 IE IE96586A patent/IE75355B1/en not_active IP Right Cessation
- 1986-04-14 ES ES553953A patent/ES8802440A1/es not_active Expired
- 1986-04-15 JP JP61087863A patent/JPS6255088A/ja active Pending
- 1986-04-15 AT AT86105183T patent/ATE139795T1/de not_active IP Right Cessation
- 1986-04-15 EP EP86105183A patent/EP0198474B1/en not_active Expired - Lifetime
- 1986-04-15 EP EP95119966A patent/EP0719863A1/en not_active Withdrawn
- 1986-04-15 CN CN198686102640A patent/CN86102640A/zh active Pending
- 1986-04-15 YU YU00609/86A patent/YU60986A/xx unknown
- 1986-04-15 DE DE3650536T patent/DE3650536T2/de not_active Expired - Fee Related
- 1986-04-15 ZA ZA862797A patent/ZA862797B/xx unknown
- 1986-04-15 SG SG1996005752A patent/SG43220A1/en unknown
-
1998
- 1998-04-09 HK HK98103014A patent/HK1003794A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE139795T1 (de) | 1996-07-15 |
IE75355B1 (en) | 1997-08-27 |
ES8802440A1 (es) | 1988-06-01 |
EP0719863A1 (en) | 1996-07-03 |
JPS6255088A (ja) | 1987-03-10 |
FI861417A0 (fi) | 1986-04-01 |
IL78472A (en) | 2004-08-31 |
EP0198474A1 (en) | 1986-10-22 |
DE3650536T2 (de) | 1997-02-27 |
AP8600035A0 (en) | 1987-10-14 |
EP0198474B1 (en) | 1996-06-26 |
HK1003794A1 (en) | 1998-11-06 |
DE3650536D1 (de) | 1996-08-01 |
CN86102640A (zh) | 1987-04-08 |
ZA862797B (en) | 1988-04-27 |
ES553953A0 (es) | 1988-06-01 |
YU60986A (en) | 1988-10-31 |
IE860965L (en) | 1986-10-15 |
IL78472A0 (en) | 1986-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG43220A1 (en) | Hepatitis surface antigen formed by recombinat dna techniques vaccines diagnostics cell lines and methods of forming same | |
IL85216A0 (en) | Hepatitis b virus surface antigens and hybrid antigens containing them | |
PH25249A (en) | Method for producing hepatitis b virus proteins in yeast | |
IL79111A0 (en) | Compositions and methods for functionalizing nucleic acids | |
GR871460B (en) | Vaccine and method of preparation | |
ZA868798B (en) | Agricultural-chemical-producing endosymbiotic microorganisms and method of preparing and using same | |
DE3474775D1 (en) | Method for purification of hepatitis b virus surface antigen | |
EP0102731A3 (en) | Methods for preparation of hepatitis b surface antigen free gamma globulins and products | |
EP0287030A3 (en) | Immunological methods and materials for detection of tumor associated antigens | |
PT85137A (en) | T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen | |
IL78874A0 (en) | Method of preparing vaccines and process for the production thereof | |
ZA861767B (en) | Process for preparing hepatitis b surface antigen containing particles in novel forms which are highly immunogenic | |
EP0232410A4 (en) | CLEAVAGE PROCESS AND BUFFER FOR THE EXTRACTION OF HEPATITIS B SURFACE ANTIGENS FROM YEAR CELLS. | |
JPS54141790A (en) | Modified dna and method of manufacturing hybrid protein using it | |
DE3162469D1 (en) | Method of growing hepatitis b surface antigen | |
OA08238A (en) | Hepatitis B surface antigen formed by recombinant DNA techniques vaccines diagnostics cell lines and methods of forming same | |
GB2181434A (en) | Hepatitis b virus vaccine and process for its preparation | |
ZA868612B (en) | Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells | |
IE861419L (en) | Isolation of hepatitis b surface antigen | |
GR862721B (en) | Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells | |
ZA868611B (en) | Fermentation methods for hepatitis vaccine production | |
SG139793G (en) | Preparation of hepatitis B surface antigen in yeast. | |
PH19948A (en) | Vaccines and method of preparation thereof | |
IE871644L (en) | T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen | |
IE872543L (en) | Vaccine and method of preparation |